pharma · Hereditary Angioedema · Diabetic Macular Edema · KALV
Kalvista Pharmaceuticals (Ireland)
Kalvista Pharmaceuticals (Ireland) Limited
Kalvista Pharmaceuticals (Ireland) clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Framingham, USA
- Employees
- 279
- Programs
- 8
- Drugs
- 6
- Patents
- 24
Kalvista Pharmaceuticals (Ireland) projects
8 ClinicalTrials.gov programs sponsored by Kalvista Pharmaceuticals (Ireland).
Kalvista Pharmaceuticals (Ireland) has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
KVD900 150 mg
Kalvista Pharmaceuticals (Ireland) Limited
Hereditary Angioedema
1 trial -
KVD900 600 mg
Kalvista Pharmaceuticals (Ireland) Limited
Hereditary Angioedema
2 trials -
Placebo
Kalvista Pharmaceuticals (Ireland) Limited
Hereditary Angioedema
1 trial -
KVD001 Injection
Kalvista Pharmaceuticals (Ireland) Limited
Diabetic Macular Edema
2 trials -
KVD824
Kalvista Pharmaceuticals (Ireland) Limited
Angioedema, Hereditary, Types I and II
1 trial -
KVD900
Kalvista Pharmaceuticals (Ireland) Limited
Hereditary Angioedema
2 trials -
KVD824
Kalvista Pharmaceuticals (Ireland) Limited
Hereditary Angioedema
1 trial -
KVD824 Prototype 1 modified-release tablet
Kalvista Pharmaceuticals (Ireland) Limited
Hereditary Angioedema
1 trial
Frequently asked questions
How many clinical projects does Kalvista Pharmaceuticals (Ireland) have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.